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Abstract
Background: Hepatitis B virus (HBV) infection in diffuse large B-cell lymphoma (DLBCL) patients
is a common complication in China. However, the clinical relevance of HBV infection with respect
to DLBCL disease stages and patient survival remains unclear. The main objective of the current
study was to analyze the clinical features and to evaluate the prognostic factors of HBV infection
in DLBCL patients.
Methods: In this retrospective study, DLBCL patients were divided into two groups as HBsAg-
positive (n = 81) and HBsAg-negative (n = 181) patients. The HBsAg-positive patients were further
divided into two subgroups based on their hepatic function during chemotherapy. Various statistical
analyses were used to determine the significance of the relevant clinical parameters.
Results: Compared with the HBsAg-negative group, the HBsAg-positive DLBCL group displayed
a younger median onset age (46 year vs 51), more advanced stage at grade III/IV (58% vs 42%, p =
0.016), and more frequent hepatic dysfunction before (21% vs 5.5%, p < 0.001) and during (49.4%
vs 16.6%, p < 0.001) chemotherapy. Female DLBCL patients exhibited a higher frequency of HBsAg
positivity (p = 0.006). However, in both groups the median overall survival (OS) duration (55.8 vs
66.8 months) and response rates (91% vs 90.4%) were similar. In the HBsAg-positive DLBCL group,
the poor prognostic factors were advanced stage (p < 0.001) and hepatic dysfunction during
chemotherapy (p = 0.02). The OS of HBsAg-positive patients with hepatic dysfunction during
chemotherapy was significantly shorter than those without liver dysfunction (p = 0.016), and the
OS rates at 3 years were 48% and 72%, respectively. The use of rituximab did not increase the rates
of liver dysfunction in HBsAg-positive DLBCL patients.
Conclusion: Compared with HBsAg-negative patients, the HBsAg-positive DLBCL patients had
earlier onset and more advanced stage. The disease stage and hepatic dysfunction during
chemotherapy and were two significant prognostic factors in the HBsAg-positive DLBCL patients.
This study suggests that prophylactic treatment of HBV may be of great importance in the cases of
HBsAg-positive patients.
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Background
Hepatitis B virus (HBV) infection is the most common
cause of chronic liver disease worldwide, and China is a
highly endemic area of HBV infection with approximately
170 million carriers [1]. Previous studies have found a
high prevalence of hepatitis B virus infection in non-
Hodgkin's lymphoma (NHL) [2,3]. We have recently
reported that HBV prevalence in B-cell NHL patients was
approximately 30.2%, which was significantly higher
than the HBV infection rates in T-cell NHL (19.8%) and in
other cancers (14.8%) [4]. Moreover, HBsAg-positive B-
cell NHL patients had an earlier disease onset than those
without HBV infection. Previous studies also detected the
presence of HBsAg in bone marrow cells of lymphoma
[5]. Based on these findings, we hypothesized that HBV
might play an important role in the development of B-cell
NHL, and that the HBsAg-positive B-cell NHL patients
could be considered a clinically distinct subgroup [4].
It is generally accepted that chemotherapy can reactivate
prior HBV infection in patients with positive hepatitis B
surface antigen (HBsAg) [6]. The reactivation rates of HBV
are in the range of 20%–50% [7], and the mortality rates
in these patients are 10%–40% [8]. Thus, chemotherapy-
induced HBV reactivation in diffuse large B-cell lym-
phoma patients who are HBsAg-positive has been consid-
ered a serious complication, which is associated with
long-term deterioration of hepatic function [9]. Certain
therapeutic agents such as glucocorticoids and rituximab
used in the chemotherapeutic regimens for diffuse large B-
cell lymphoma are considered risk factors for HBV reacti-
vation [10].
Due to the risk of HBV reactivation during chemotherapy,
preemptive treatment using interferon or lamivudine (a
reverse-transcriptase inhibitor of HBV DNA polymerase)
is usually recommended in HBsAg-positive patients when
they are undergoing chemotherapy [11-16]. However, few
studies have focused on the prognosis of HBsAg-positive
DLBCL patients. It is also unknown whether there is any
survival benefit in patients who received anti-virus treat-
ment. In this retrospective study, we compared the clinical
features of diffuse large B-cell lymphoma patients with or
without HBV infection, and evaluated the potential prog-
nostic factors in diffuse large B-cell lymphoma patients
with HBsAg-positive with stratified by various clinical fea-
tures and liver function.
Methods
Study Samples
We analyzed diffuse large B-cell lymphoma patients who
had received histological diagnosis and treatment in Sun
Yat-sen University Cancer Center from January 1999 to
June 2006. This retrospective study was conducted in
compliance with the institutional policy to protect patient
private information, and was approved by the Institution
Review Board (IRB) of Sun Yat-sen University Cancer
Center. Informed consents were obtained from all
patients before the collection of patient information and
serum samples for analyses using Enzyme-linked immu-
nosorbent assay (ELISA) to detect hepatitis B surface anti-
gen (HBsAg), hepatitis B surface antibody (anti-HBs),
hepatitis B e antigen (HBeAg), hepatitis B e antibody
(anti-HBe) and hepatitis B core antibody (anti-HBc). All
patients were also tested for serum human immunodefi-
ciency virus (HIV) antibody, HAV antibody, HCV anti-
body, HDV antigen, HDV antibody and HEV antibody.
Patients were excluded from this study if they exhibited
histological transformation from low-grade lymphoma,
positive serology with HIV or HCV, previous or secondary
cancer without treatment. Patients with abnormal liver
tests (WHO grade >; 2) were included only if such abnor-
malities were related to lymphoma involvement.
Liver function tests and definition of hepatic dysfunction
Routine liver function tests included alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), galactosyl-
hydroxylysyl glucosyltransferase (GGT), and bilirubin
(direct and indirect forms). These assays were performed
within one week before the start of each cycle of chemo-
therapy. Hepatic dysfunction was classified into 4 degrees
according to the NCI Common Toxicity Criteria (CTC)
Manual Version 2.0.
Treatment
For early stage patients (stage I or II), four to six cycles of
standard CHOP or R-CHOP regimen were given accord-
ing to treatment responses and the IPI scores. After chem-
otherapy, patients were given regional radiation therapy
(RT) to the involved body regions. For patients in
advanced stages or in early stage with bulky disease, six to
eight cycles of CHOP, R-CHOP or CHOP-based more
aggressive regimen were given. RT was given to patients
with residual disease. Patients with bulky disease in any
stage were routinely given RT. Relapse or refractory
patients were administrated salvage chemotherapy regi-
men such as EPOCH, ICE with or without rituximab.
Autologous stem cell transplantation was recommended
to patients when indicated. Once patients showed abnor-
mal liver function evidenced by the tests, they were given
hepatinica (diammonium glycyrrhizinate, compound gly-
cyrrhizin, reduced glutathione, or polyene phosphatidyl
choline) with or without Lamivudine. Chemotherapy
continued after the liver function returned to normal.
Response criteria
Response was evaluated according to the standard
response criteria (physical examination, CT scan, and
bone marrow biopsy), and imaging studies were per-
formed every 2 cycles during chemotherapy [17]. A com-BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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plete response was defined as the disappearance of all
signs of disease for at least one month or an absence of
change in minimal residual radiographic abnormalities
for at least six months. A partial response was defined as a
reduction by at least 50% in the sum of the products of the
largest perpendicular diameters of all measurable lesions
for at least one month. Stable disease was defined as a
regression of any measurable lesion by less than 50%, or
no change in the non-measurable lesions and without the
growth of the existing lesions or the appearance of new
lesions. Progressive disease was defined as an increase of
at least 25% in the sum of the products of the largest per-
pendicular diameters from nadir, or a new lesion larger
than 2 cm as revealed by radiography or 1 cm detected by
physical examination, or involvement of the bone mar-
row in a patient who had a prior complete response or a
clinical complete response.
Follow-up
After treatment, routine clinical follow-up was conducted
every 3 months for the first 2 years and then every 6
months for additional 3 years. Ultrasound or computed
tomography scan was performed every six months during
the first two years and then annually afterward during the
follow-up period.
Statistical analysis
Statistical differences in the baseline clinical parameters
and treatment characteristics between the HBsAg-positive
patients and HBsAg-negative patients were evaluated by
either chi-square test or Fisher's exact test for categorical
parameters, and Mann-Whitney U test for continuous var-
iables. Overall survival (OS) and survival curves were cal-
culated by Kaplan-Meier method and the differences
between two groups were compared by log-rank test. OS
was calculated from the date of diagnosis to the date of
death or the last follow-up. The multivariate analysis of
outcome in terms of OS was performed by Cox regression,
which included the variables that were significant in uni-
variate analysis. A two-tailed p value of less than 0.05 was
considered statistically significant. Statistical analysis was
performed with SPSS for Windows V. 13.0.
Results
A total of 262 diffuse large B-cell lymphoma patients who
received chemotherapy were included in this study. There
were 81 patients in the HBsAg-positive group and 181
patients in the HBsAg-negative group. One patient in the
HBsAg-positive group had HEV co-infection. All patients
were HIV-negative. The baseline clinical parameters and
treatment characteristics of the patients in both groups are
shown in Table 1. The median follow-up time of all
patients was 30 months in the HBsAg-positive group and
28 months in the HBsAg-negative group. The HBsAg-pos-
itive group was associated with advanced stage (58%
HBsAg-positive vs 42% HBsAg-negative, p = 0.016), more
female gender (49.4% vs 31.5%, p = 0.006), more liver
involvement (9.9% vs 2.8%, p = 0.027), more spleen
involvement (14.8% vs 6.2%, p = 0.024), and more
hepatic dysfunction before (21% vs 5.5%, p < 0.001) or
during chemotherapy (49.4% vs 16.6%, p < 0.001). The
median onset age in the HBsAg-positive group was
younger than the HBsAg-negative group (46 vs 51 years, p
= 0.026). No significant difference was found between the
two groups in their IPI scores, LDH levels, chemotherapy
cycles, radiation therapy and response rates. More than
90% of the patients were given CHOP-based regimen as
the first line chemotherapy in the two groups. Three
HBsAg-positive patients showed grade 3 abnormal liver
function and one patient with grade 4 abnormal liver
function before chemotherapy, likely due to the liver
involvement of lymphoma. As shown in Table 1, the
occurrence of hepatic dysfunction was much higher in
HBsAg-positive group than that in the negative group.
Hepatic dysfunction after chemotherapy was not signifi-
cantly correlated with liver function status before chemo-
therapy (p = 0.082). The response rates in the HBsAg-
positive and -negative groups were 91% and 90.4%,
respectively (p = 0.25).
The projected median overall survival in HBsAg-positive
patients was 55.8 months compared to 66.8 months in
the HBsAg-negative patients (p = 0.85, Figure 1). Multiple
clinical parameters were then used to analyze the progno-
sis of the HBsAg-positive patients and to compare the sur-
vival differences between the HBsAg-positive and -
negative groups. As shown in Table 2, disease stages, radi-
ation, and intra-chemotherapy hepatic dysfunction were
significant factors that affected patient survival in HBsAg-
positive patients. In the COX regression analysis, only dis-
ease stage (Figure 2) and hepatic dysfunction (Figure 3)
during chemotherapy showed a significant impact on
overall survival, with the p values of <; 0.001 and 0.02,
respectively.
Then we divided the 81 HBV-positive patients into two
subgroups based on their hepatic function during chemo-
therapy. There were 40 patients who showed at least one
time hepatic dysfunction and 41 patients who showed
normal liver function during chemotherapy. The charac-
teristics of both subgroups are shown in Table 3. The two
subgroups were comparable in most clinical parameters
except radiation therapy (20% v 40.5%, p = 0.037).
Twenty-two patients in the hepatic dysfunction sub-group
and twenty-one patients in the normal liver function sub-
group received lamivudine during chemotherapy. Eight
patients in the normal liver function sub-group had suf-
fered hepatic dysfunction before chemotherapy, whose
liver function turned into normal after administration of
lamivudine and hepatinica. The difference in lamivudineBMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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administration between the two sub-groups was not sig-
nificant (p-value 0.13).
In the HBsAg-positive DLBCL group, only one patient was
not given steroid due to the abnormal liver function
before chemotherapy. Four patients in the hepatic dys-
function group and five patients in the normal liver func-
tion group required dose reduction due to hepatic
dysfunction or other comorbidities. Twenty-seven
patients were given rituximab for at least 2 cycles, which
did not increase the intra-chemotherapy hepatic dysfunc-
tion rate (Table 4). The patients received rituximab
appeared to have a higher complete remission rate than
those who did not (70.4% vs 44.4%). However, the statis-
tics shows that this difference did not reach significance (p
= 0.16, Table 5), probably due to the small sample size.
The total numbers of chemotherapy and rituximab
administration were similar between the patients with or
without intra-chemotherapy liver dysfunction. Five
patients were give autologous bone marrow transplanta-
tion after recurrence. Three of them exhibited hepatic dys-
Table 1: Comparison of HBsAg-positive patients with HBsAg-negative patients
HBsAg-positive patients 
(No = 81)(30.9%)
HBsAg-negative patients 
(No = 181)(69.1%)
p-value
Age (years) 0.026
Range 17–75 17–86
Median 46 51
Sex 0.006
Male 41(50.6) 124(68.5)
Female 40(49.4) 57(31.5)
Stage 0.016
I/II 34(42) 105 (58)
III/IV 47(58) 76(42)
Liver involvement 0.027
Yes 8(9.9) 5(2.8)
No 73(90.1) 176(97.2)
Spleen involvement 0.024
Yes 12(14.8) 11(6.1)
No 69(85.2) 170(93.9)
LDH increase 0.89
> normal 40(49.4) 91(50.3)
normal 41(50.6) 90(49.7)
Extra node involvement 0.034
≤ 1 69(85.2) 169(93.4)
> 1 12(14.8) 12(6.6)
PS 0.26
≤ 1 76(93.8) 162(89.5)
> 1 5(6.2) 19(10.5)
IPI 0.99
0,1 46(57) 103(57)
2,3,4 35(43) 78(43)
Chemotherapy 0.69
Range 1–20 1–16
Median 6 6
Radiation 0.61
Yes 26(32.1) 64(35.4)
No 55(67.9) 117(64.6)
Response 0.24
CR 43(53) 103(61.7)
PR 31(38) 48(28.7)
SD 5(6) 8(4.8)
PD 3(3) 8(4.8)
NA 14
Hepatic dysfunction before 
chemotherapy
17(21) 10(5.5) < 0.001
Hepatic dysfunction during 
chemotherapy
40(49.4) 30(16.6) < 0.001BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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function and two of them showed sustained normal liver
function during chemotherapy.
The response rates to chemotherapy in the hepatic dys-
function subgroup and normal liver function subgroup
were similar (92.5% vs 90.3%). Among the patients who
had hepatic dysfunction during chemotherapy, the per-
centage of hepatic dysfunction with grade 1 to grade 4 was
30%, 30%, 10% and 30% respectively. Thirteen of them
had delayed chemotherapy (1–4 weeks, median 2 weeks)
because of abnormal liver function. In the HBsAg-positive
patients who experienced hepatic dysfunction, ten
patients stopped receiving chemotherapy because of
severe abnormal hepatic function with a median 5 cycles
of chemotherapy. In these 10 patients, 6 achieved CR and
4 achieved PR at the abeyance. During follow up, 4 out of
6 CR patients eventually had disease recurrence. Fourteen
patients in the hepatic dysfunction subgroup and twelve
patients in the normal liver function subgroup were given
second-line chemotherapy after disease progression or
recurrence.
The HBsAg-positive patients with hepatic dysfunction
during chemotherapy had a shorter median OS (46.7
months, 95% CI of 23.5-70 months, p = 0.016, Figure 4),
while the median OS of patients with normal liver func-
tion have not been reached. The overall survival rates at 3
years were 48% in hepatic dysfunction patients and 72%
in normal hepatic function group. The impact of liver dys-
function on OS remained significant (p = 0.02) in the
multivariate analysis (RR = 2. 6; 95% CI, 1.16-5.8).
Another factor that significantly affected OS was advanced
stage (RR = 2.5; 95% CI, 1.53-4.1). Other factors such as
age, gender, radiation therapy, and LDH were not statisti-
cally significant.
As shown in Figure 4, the overall survival of HBsAg-posi-
tive patients with normal liver function appeared higher
than that of HBsAg-negative patients. Nevertheless, this
Comparison between HBsAg-positive and HBsAg-negative DLBCL patients in overall survival Figure 1
Comparison between HBsAg-positive and HBsAg-negative DLBCL patients in overall survival.
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Table 4: Hepatic dysfunction occurrence rates based ons Rituximab administration
Use of rituximab Patients with hepatic dysfunction (N = 40) (49.4%) Patients without hepatic dysfunction (N = 41) (50.6%) p-value
Yes 13 (32.5) 14(34.1) 0.88
No 27(67.5) 27(65.9)BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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difference did not reach statistical significance (p = 0.09),
likely due to the relatively small sample size. Likewise the
survival difference between HBsAg-positive patients with
liver dysfunction and HBsAg-negative patients was not
significant. (p = 0.6)
Discussion
In this study, the proportion of HBsAg-positive cases in
diffuse large B-cell lymphoma patients was 30.1%, which
was consistent with our previous observation [4]. The
prevalence of HBV infection among DLBCL patients in
our study was comparable with the results reported by two
other groups [18,19]. The incidence of hepatic dysfunc-
tion in HBsAg-positive diffuse large B lymphoma patients
was nearly 49.4%, which was similar to another report in
Chinese patients [20]. HBsAg-positive DLBCL patients
also had an earlier median onset age. Moreover, we found
that those patients displayed higher proportion in
advanced disease stages, liver or spleen involvement, and
hepatic dysfunction before and during chemotherapy. A
higher proportion of these patients were females. How-
ever, the overall survival in patients with and without HBV
infection showed no difference. In the report by Soon-
Thye Lim et al, the characteristics of HBsAg-positive
patients with lymphoma were also similar to those who
were HBV-negative in terms of age, ECOG, extra-nodal
involvement, LDH level, stage, complete remission rate,
and overall survival [21].
We also compared the characteristics between patients
with hepatic dysfunction during chemotherapy and those
without hepatic dysfunction in HBsAg-positive DLBCL
Table 2: Univariate and multivariate logistic regression analysis of HBsAg-positive DLBCL patients
Factor Median Overall survival (months) p-value in univariate analysis p-value in multivariate analysis
Sex 0.96 -
Male 50
Female 55.9
HBeAg -
+ NA 0.39
-5 5 . 9
Staging 0.001 < 0.001
I1 3
II 21
III 23
IV 24
B symptom 0.2 -
Yes NA
No 55.9
Age(years) 0.21 -
> 60 NA
≤ 60 55.9
LDH 0.17 -
> normal 46.7
normal 55.9
Extranodal sites 0.47 -
> 13 7 . 5
0–1 55.9
PS 0.23 -
0–1 55.8
2–4 NA
Radiation therapy 0.004 0.093
Yes NA
No 46.7
Pre-CT hepatic dysfunction 0.66 -
Yes NA
No 55.9
Intra-CT hepatic dysfunction 0.016 0.02
Yes 46.7
No NA
Rituximab 0.5 -
Yes NA
No 55.9BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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patients. Although only radiation was significantly differ-
ent, there was a trend that patients with older age or more
advanced stage were more likely to develop hepatic dys-
function during chemotherapy. No previous study had
focused on the long-term survival in HBsAg-positive NHL
patients. In the current study, we demonstrated that the
diffuse large B-cell lymphoma patients with hepatic dys-
function during chemotherapy had a shorter overall sur-
vival compared with those with normal liver function
during chemotherapy. Our COX analysis showed that ear-
lier stage and continuous normal liver function during
chemotherapy were factors associated with longer overall
survival. As shown in Figure 3, in the HBsAg-positive
DLBCL group, the OS were different between patients
with and without intra-chemotherapy hepatic dysfunc-
tion. However, the p value of 0.09 was not statistically sig-
nificant, likely due to small number of patients in this
study. The mechanism of shorter OS in patients suffering
hepatic dysfunction during chemotherapy remains
unknown. In some of the patients with hepatic dysfunc-
tion, the scheduled chemotherapy was incompliant due
to various reasons, which might contribute to suboptimal
treatment. When compared with the hepatic dysfunction
patients, the normal liver function patients had higher
complete remission rate (61% vs 45%).
Previous studies suggest that deterioration in liver reserve
developed more frequently in patients with HBV reactiva-
tion [12,22]. In our study, among the forty patients who
suffered from hepatic dysfunction during chemotherapy,
seventy-five percent of them had normal liver function
before treatment. This result suggested that abnormal liver
function during chemotherapy may be related to chemo-
therapy instead of deteriorated liver function before
chemotherapy. The hepatic dysfunction during chemo-
therapy may be a reflection of the reactivation of HBV
Comparison of Overall survival in HBsAg-positive DLBCL patients based on different Stages Figure 2
Comparison of Overall survival in HBsAg-positive DLBCL patients based on different Stages.
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Table 5: Comparison of Response in HBsAg-positive patients treated with or without rituximab
Use of rituximab (N = 27) (33.3%) No rituximab (N = 54) (66.7%) p-value
Complete response 19 (70.4) 24(44.4) 0.16
Partial response 6 (22.2) 25(46.3)
Stable disease 1(3.7) 3(5.6)
Progressive disease 1(3.7) 2(3.7)BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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[23]. Nevertheless, the impact of the HBV reactivation on
DLBCL patients is still not fully understood [24-27].
It is commonly recognized that HBV reactivation was
more likely to develop in patients with NHL than with
other malignancies. Hepatitis provoked by reactivation of
HBV is a well recognized complication in lymphoma
patients with chronic HBV infection undergoing cytotoxic
or immunosuppressive therapy.
Some reports suggest that rituximab treatment may
deplete CD20+ B-cells and lead to impaired humoral
immune responsiveness [28]. Other studies revealed that
patients with HBV infection developed severe reactivation
or fulminating hepatitis after administration of rituximab
[29,30]. Because B lymphocytes can act as antigen-pre-
senting cells during the immune attack against HBsAg-
positive hepatocytes, depletion of B-cells by rituximab
might play a role in HBV evading immune recognition
and clearance, and thus might contribute to the viral per-
sistence. However, in our study, administration of rituxi-
mab did not increase the incidence of intra-chemotherapy
hepatic dysfunction and the addition of rituximab to
chemotherapy regimens did not affect patient tolerance to
chemotherapy. It seems that R-CHOP administration is
safe for the HBsAg-positive DLBCL patients in our study.
Masahiro Kami also reported that most patients with HBV
infection tolerated rituximab plus chemotherapy without
developing major adverse events [31]. Since we did not
test liver function regularly after the chemotherapy was
completed, it is unclear if in these patients there were
undetected delayed HBV reactivation, which are known to
occur in other studies [32,33].
An Italian group has shown that hepatitis C virus-positive
diffuse large B-cell lymphoma patients with no hepatic
dysfunction at diagnosis displayed a higher 5-year OS
compared to patients with hepatitis or cirrhosis, but these
differences did not reach statistical significance [34]. We
found no survival difference between patients with and
without hepatic dysfunction before chemotherapy. Like-
wise, we did not observe any difference in incidence of
reactivation of HBV between hepatitis B surface antigen-
positive and hepatitis B surface antigen-negative patients
as suggested by another study [20].
Lamivudine has been identified as a useful drug in preven-
tion of HBV reactivation and hepatitis [11,14,16]. In our
retrospective analysis, we did not observe that the prophy-
lactic use of lamivudine could reduce the rate of hepatic
dysfunction, possibly due to suboptimal use of lamivu-
dine at the time when prophylactic use of this drug had
Comparison of overall survival between HBsAg-positive DLBCL patients with normal liver function and those with hepatic dys- function during chemotherapy Figure 3
Comparison of overall survival between HBsAg-positive DLBCL patients with normal liver function and those 
with hepatic dysfunction during chemotherapy.
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not been standardized. It was reported that irregular use
or cessation of lamivudine treatment during chemother-
apy might activate the hepatitis B virus [33]. Nevertheless,
the lamivudine administration did contribute to the
reduction of abnormal liver function markers after hepatic
dysfunction occurred. Prospective studies are required to
determine the role of lamivudine in the prevention of
hepatic dysfunction.
Conclusion
The current study showed a younger onset age, higher por-
tion of female, liver or spleen involvement, more
advanced disease in the HBsAg-positive DLBCL patient
group. There was a higher incidence of hepatic dysfunc-
tion before or after chemotherapy in HBsAg-positive
DLBCL. Moreover, a significant difference in overall sur-
vival was observed between patients with continuous nor-
mal liver function and those with hepatic dysfunction
during chemotherapy. We propose that giving prophylac-
tic treatments to prevent hepatic dysfunction during
Table 3: Characteristics of HBsAg-positive patients with hepatic dysfunction and without hepatic dysfunction during chemotherapy
Patients with hepatic dysfunction 
(No = 40) (49.4%)
Patients without hepatic dysfunction 
(No = 41) (50.6%)
p-value
Sex 0.22
Male 23(57.5) 18(43.9)
Female 17(42.5) 23(56.1)
Age (years) 0.096
≤ 60 28(70) 35(85.4)
> 60 12(30) 6(14.6)
Staging 0.088
I/II 13(32.5) 21(51.2)
III/IV 27(67.5) 20(48.8)
B symptom 0.43
Positive 15(37.5) 12(29.3)
Negative 25(62.5) 29(70.7)
PS 0.41
0,1 38(95) 37(90.2)
2,3,4 2(5) 4(9.8)
LDH 0.75
≤ Normal value 22(55) 24(58.5)
> Normal value 18(45) 17(41.5)
Extranodal sites 0.42
0–1 34(85) 32(78)
> 1 6(15) 9(22)
Liver involvement 0.63
Yes 7(17.5) 5(12.2)
No 33(82.5) 36(87.8)
Spleen involvement 0.50
Yes 12(30) 11(26.8)
No 28(70) 30(73.2)
HBV status prior to CT 0.38
HBsAg(+), HBeAg(+), Anti-HBc(+) 11(27.5) 15(36.6)
HBsAg(+), Anti-HBe(+), Anti-HBc(+) 29(72.5) 26(63.4)
Liver dysfunction prior to CT 0.38
Yes 10(25) 7(17.1)
No 30(75) 34(82.9)
Radiation 0.037
Yes 8(20) 17(41.5)
No 32(80) 24(58.5)
Chemotherapy 0.90
No. Range 2–20 1–13
Median 6 6
Response to front-line chemotherapy 0.26
CR 18(45) 25(61)
PR 19(47.5) 12(29.3)
SD 1(2.5) 3(7.3)
PD 2(5) 1(2.4)BMC Cancer 2008, 8:115 http://www.biomedcentral.com/1471-2407/8/115
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chemotherapy may prolong the overall survival of HBsAg-
positive DLBCL patients. The HBsAg-positive B-cell NHL
patients may be considered as a special patient entity who
may benefit from such treatment protocol.
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